LLY - Analysts Boost Eli Lilly's Forecast With High Hopes On Mounjaro Zepbound Performance | Benzinga
Tuesday, Eli Lilly And Co (NYSE:LLY) reported fourth-quarter of 2023 revenue of $9.35 billion, up 28% Y/Y, beating the consensus of $8.93 billion driven by increases of 16% due to higher realized prices, 11% in volume, and 1% from the favorable impact of foreign exchange rates.
New Products revenue grew by $2.19 billion to $2.49 billion in the quarter, led by Mounjaro and Zepbound. Growth Products revenue increased 9% to $5.27 billion, led by Verzenio and Jardiance.
In its fourth quarter 2023 earnings released, Eli Lilly reported results from the SYNERGY-NASH Phase 2 study of tirzepatide in adults with nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis, which met its primary endpoint where up to 74% of participants achieved an absence of MASH with no worsening of fibrosis at 52 weeks, compared to nearly ...